Literature DB >> 22539062

Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection.

S P Grekova1, Z Raykov, R Zawatzky, J Rommelaere, U Koch.   

Abstract

Rodent autonomous parvoviruses (PVs) are endowed with oncotropic properties and represent virotherapeutics with inherent oncolytic features. This work aimed to evaluate the capacity of Minute Virus of Mice (MVMp) to act as an adjuvant stimulating a mouse glioblastoma-specific immune response. MVMp was shown to induce cell death through apoptosis in glioma GL261 cells. Antigen-presenting cells (APCs) provide the initial cue for innate and adaptive immune responses, and thus MVMp-infected GL261 cells were tested for their ability to activate dendritic cells (DCs) and microglia (MG), two distinct cell types that are able to act as APCs. MG and discrete DC subsets were activated after co-culture with MVMp-infected glioma GL261 cells, as evidenced by upregulation of specific activation markers (CD80, CD86) and release of proinflammatory cytokines (tumor necrosis factor-α and interleukin-6). The in vivo analysis of immunodeficient and immunocompetent mice revealed a clear difference in their susceptibility to MVMp-mediated tumor suppression. Immunocompetent mice were fully protected from tumor outgrowth of GL261 cells infected ex vivo with MVMp. In contrast, immunodeficient animals were less competent for MVMp-dependent tumor inhibition, with only 20% of the recipients being protected, arguing for an additional immune component to allow full tumor suppression. In keeping with this conclusion, immunocompetent mice engrafted with MVMp-infected glioma cells developed a level of anti-tumor immunity with isolated splenocytes producing elevated levels of interferon-γ. In rechallenge experiments using uninfected GL261 cells, we could show complete protection against the tumor, arguing for the induction of a T-cell-mediated, tumor-specific, long-term memory response. These findings indicate that the anticancer effect of PVs can be traced back not only for their direct oncolytic effect, but also to their ability to break tumor tolerance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22539062     DOI: 10.1038/cgt.2012.20

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  24 in total

1.  Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Authors:  Guido Wollmann; Eugene Drokhlyansky; John N Davis; Connie Cepko; Anthony N van den Pol
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

2.  Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells.

Authors:  Tian Ye; Ke Jiang; Liwen Wei; Martin P Barr; Qing Xu; Guirong Zhang; Chan Ding; Songshu Meng; Haozhe Piao
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

Review 3.  Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.

Authors:  Drew A Spencer; Jacob S Young; Deepak Kanojia; Julius W Kim; Sean P Polster; Jason P Murphy; Maciej S Lesniak
Journal:  Ther Deliv       Date:  2015

4.  Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses.

Authors:  Ellen M Vollmers; Peter Tattersall
Journal:  Virology       Date:  2013-08-09       Impact factor: 3.616

5.  Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.

Authors:  Assia L Angelova; Svitlana P Grekova; Anette Heller; Olga Kuhlmann; Esther Soyka; Thomas Giese; Marc Aprahamian; Gaétan Bour; Sven Rüffer; Celina Cziepluch; Laurent Daeffler; Jean Rommelaere; Jens Werner; Zahari Raykov; Nathalia A Giese
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

Review 6.  Glioma virus therapies between bench and bedside.

Authors:  Johanna K Kaufmann; E Antonio Chiocca
Journal:  Neuro Oncol       Date:  2014-01-26       Impact factor: 12.300

7.  MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.

Authors:  Miika Martikainen; Minna Niittykoski; Mikael von und zu Fraunberg; Arto Immonen; Susanna Koponen; Maartje van Geenen; Markus Vähä-Koskela; Erkko Ylösmäki; Juha E Jääskeläinen; Kalle Saksela; Ari Hinkkanen
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

Review 8.  Parvovirus Capsid-Antibody Complex Structures Reveal Conservation of Antigenic Epitopes Across the Family.

Authors:  Shanan N Emmanuel; Mario Mietzsch; Yu Shan Tseng; James Kennon Smith; Mavis Agbandje-McKenna
Journal:  Viral Immunol       Date:  2020-04-21       Impact factor: 2.257

Review 9.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

10.  Parvoviruses-tools to fine-tune anticancer immune responses.

Authors:  Svitlana P Grekova; Jean Rommelaere; Zahari Raykov
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.